Tharimmune Secures Global Licensing for Avior’s AV104 Therapy
Tharimmune Inc. Announces Licensing Agreement with Avior
On November 6, Tharimmune Inc., based in Bridgewater, N.J., announced it had executed a global licensing agreement with Avior for the Cary company’s AV104 therapy. AV104 is an oral thin film – a method of drug delivery involving absorption in the mouth – that targets pruritus associated with chronic liver disease.
Renaming and Regulatory Plans
Tharimmune stated it would rename the compound to TH104 and seek regulatory approval for the treatment of pruritus in patients with a rare liver disease known as primary biliary cholangitis (PBC).
CEO Statement
“This license agreement allows the company to bring a clinical-stage asset into the organization as we shift into a business model focused on clinical development, signifying our next step as we grow into a patient-focused biotechnology organization,” said Tharimmune CEO Randy Milby in a news release.
Avior Bio 